Combination Therapy with DETA/NO and Clopidogrel Inhibits Metastasis in Murine Mammary Gland Cancer Models via Improved Vasoprotection.

Abstract

Vascular endothelial dysfunction and platelet activation play a key role in tumor metastasis, and therefore, both of these processes are considered important therapeutic targets in cancer. The aim of our studies was to analyze antimetastatic activity of combination therapy using nitric oxide donor DETA/NO and antiplatelet drug clopidogrel. Nitric oxide acts as a vasoprotective mediator, while clopidogrel inhibits ADP-mediated platelet aggregation. 4T1-luc2-tdTomato cell line transplanted intravenously (i.v.) and 4T1 cell line transplanted orthotopically were used as metastatic mammary gland cancer models. Moreover, antiaggregation action of compounds was tested ex vivo on the blood samples taken from breast cancer patients. We have shown that in selected dosage regimes, DETA/NO combined with clopidogrel significantly reduced lung metastatic foci formation in an i.v. model, and such inhibition was transiently observed also in an orthotopic model. The antimetastatic effect was correlated with a significant increase of prostacyclin (PGI2) metabolite and reduction of endothelin-1, sE-selectin, sI-CAM, and TGF-β plasma levels as well as decreased V-CAM expression on the endothelium. Combination therapy decreased fibrinogen binding to the resting platelets at the early stage of tumor progression (day 14). However, at the later stages (days 21 and 28), the markers of platelet activation were detected (increased JON/A antibody bound, P-selectin level, binding of fibrinogen, and vWf). Decreased aggregation as well as a lower release of TGF-β were detected in platelets incubated ex vivo with compounds tested from metastatic breast cancer patients. Although combination therapy increases E-cadherin, the increase of N-cadherin and α-SMA in tumor tissue was also observed. The results showed that at the early stages of tumor progression, combined therapy with DETA/NO and clopidogrel improves vasoprotective and antiplatelet activity. However, in advanced tumors, some adverse effects toward platelet activation can be observed.

• Authors: Kseniia Porshneva, Diana Papiernik, Mateusz Psurski, Marcin Nowak, Rafał Matkowski, Marcin Ekiert, Magdalena Milczarek, Joanna Banach, Joanna Jarosz, Joanna Wietrzyk
• Journal: Molecular pharmaceutics (Mol Pharm) Vol. 15 Issue 11 Pg. 5277-5290 (11 05 2018) ISSN: 1543-8392 [Electronic] United States
• PMID: 30234992 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene
• Nitric Oxide Donors
• Platelet Aggregation Inhibitors
• Triazenes
• Clopidogrel

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Breast Neoplasms (blood, drug therapy)
• Cell Line, Tumor (transplantation)
• Clopidogrel (administration & dosage)
• Endothelium, Vascular (drug effects, pathology)
• Female
• Humans
• Mammary Neoplasms, Experimental (blood supply, drug therapy, pathology)
• Mice
• Mice, Transgenic
• Nitric Oxide Donors (administration & dosage)
• Platelet Activation (drug effects)
• Platelet Aggregation Inhibitors (administration & dosage)
• Platelet-Rich Plasma (drug effects)
• Triazenes (administration & dosage)